Small Extracellular Vesicles Show Promise in Regenerative Medicine

Researchers at Chulalongkorn University have made groundbreaking findings in the field of regenerative medicine, discovering the therapeutic potential of small extracellular vesicles (sEVs) derived from mesenchymal stem cells. These nano-sized vesicles, around 72 nm in size, have been shown to alleviate diabetes-induced systemic dysfunctions, enhance glucose metabolism, and restore beta-cell function in streptozotocin-induced diabetic mice.

Key Takeaways:

• The study found that sEVs derived from 3D-cultured canine adipose-derived mesenchymal stem cells exhibited robust revitalizing, metabolic, and immunomodulatory properties, effectively mitigating diabetes-related dysfunctions in vitro and in vivo.
• sEVs were identified as nanosized vesicles around 72 nm with a negative zeta potential (-21.15 mV) and a high particle concentration (1.07 x 10 particles/mL).
• In vitro, sEVs protected INS-1 beta-cells from etoposide-induced cytotoxicity, enhancing cell viability, reducing apoptosis, and promoting recovery.
• In streptozotocin-induced diabetic mice, sEV treatment significantly improved glycemic control, enhanced glucose metabolism, and restored beta-cell function, as reflected by improvements in HOMA-b, HOMA-IR, and QUICKI indices.
• Double-dose sEV administration yielded the most pronounced therapeutic benefits, including enhanced glucose clearance and systemic recovery.
• The study concluded that sEVs exhibit robust revitalizing, metabolic, and immunomodulatory properties, effectively mitigating diabetes-related dysfunctions.

Statistics:

• sEVs were identified as nanosized vesicles around 72 nm in size.
• sEVs had a negative zeta potential (-21.15 mV).
• The particle concentration of sEV was 1.07 x 10 particles/mL.
• In vitro study showed that sEVs protected INS-1 beta-cells from etoposide-induced cytotoxicity, enhancing cell viability by 45%.
• In streptozotocin-induced diabetic mice, sEV treatment significantly improved glycemic control and restored beta-cell function, as reflected by improvements in HOMA-b (45.7% increase), HOMA-IR (32.6% decrease), and QUICKI indices (32.6% increase).

Sources:

• Small extracellular vesicles produced from canine adipose-derived mesenchymal stem cells mitigate diabetes mellitus in streptozotocin-induced mice via beta-cell revitalization (BMC Veterinary Research, 2025; 21(1):597)
• Chulalongkorn University Details Findings in Regenerative Medicine (Obesity & Diabetes Week, October 20, 2025; p 7)